EDITORS NOTE: All content, references and quotes for this article were gathered from the Benchling Case study as well as other available online sources.
‘In the life sciences today, the promise of AI is omnipresent—yet its impact hinges on the less glamorous work of building strong data foundations. Industry surveys indicate that unclear data strategy and fragmented systems remain among the top obstacles to realizing AI’s potential in R&D. For many organizations, the challenge is not simply adopting new analytics tools, but first breaking free from silos and manual processes that slow decision-making and undercut collaboration.
Consider the experience of MacroGenics, as shared in a recent Benchling case study. The Rockville, MD based innovator in antibody-based cancer therapeutics has long managed integrated biologics capabilities spanning discovery through clinical trials. As several candidates are advancing and the desire to increase speed of IND filings, MacroGenics recognized that lingering paper-based records and disparate data capture were impeding speed. “She used to spend 30 minutes a day just dropping printouts into a lab notebook,” recalls Associate Scientist Manasi Nawathe—and that was time better spent on experimental design and analysis. By selecting a unified digital platform to bring Research and BioPharmaceutical Development (BPD) teams onto the same system, MacroGenics not only standardized how data is recorded and shared, but also freed scientists to focus on high-value work and cross-functional collaboration.
This shift delivered immediate wins: process development teams could model recipes, execute batches, and automatically capture analytical results in structured formats. As Senior Scientist Nathalie Gerassimov notes, having data organized and searchable accelerates regulatory filings and preserves institutional knowledge over years of development. Such user-centric design—configuring templates aligned to specific workflows so that scientists transition smoothly from paper to digital—drove rapid adoption in the first month, demonstrating that technology must align with how teams actually work rather than forcing rigid new processes.
Why does this matter for AI? Simply put, machine learning and advanced analytics require clean, well-annotated datasets to generate reliable insights. Industry reports find that up to 80% of AI initiatives stall due to poor data foundations, unclear governance, or inconsistent workflows. When data remains trapped in PDFs, spreadsheets, or siloed labs, models cannot learn from the full breadth of historical experiments. By contrast, organizations that invest in unified data platforms establish a shared “language” across antibody engineering, analytical sciences, and process development teams—ensuring that critical metadata, assay results, and sample histories feed directly into predictive models.
Beyond internal R&D, the same digital data framework can also support MacroGenics’ CDMO services. MacroGenics is applying its antibody development experience and a standardized digital workflow to support both emerging companies and established partners. By helping partners align on data governance and workflow templates, MacroGenics can support smoother tech transfer, clearer documentation, and compliance-ready execution.. This collaborative model underscores how an organization’s own digital maturity can become a market differentiator, reinforcing its reputation as a trusted innovation leader.
Looking ahead, the convergence of structured data and AI opens frontiers in antibody discovery and development. Machine learning models trained on curated historical process and assay data can predict developability, stability, or immunogenicity earlier, reducing costly failures down the line. Large Language Models applied to digital lab notebooks could surface hypotheses or flag anomalies before they derail projects. Yet these advances depend on having the right data architecture in place today. As MacroGenics continues to mature its data practices over time, it aims to ensure that information is well organized and accessible, creating opportunity to evaluate emerging analytical approaches in the future.
Of course, digital transformation extends beyond technology selection. Change management, governance structures, and talent alignment are equally vital. Successful adopters invest early in data stewardship roles, standardized templates, and cross-functional steering committees that ensure data quality and access. They also celebrate early wins—such as faster analytical reviews or streamlined sample handoffs—to sustain momentum. MacroGenics’ approach of configuring modules to mirror existing workflows, combined with visible productivity gains (“we can now present directly from our digital entries in meetings”), exemplifies how to win user buy-in and pave the way for AI readiness.
For life science professionals evaluating their own data management strategies, the lesson is clear: prioritize building an integrated, user-centric data platform before layering on advanced analytics. Assess current pain points—manual notebook work, siloed inventories, or slow regulatory data retrieval—and consider partners or platforms that offer role-specific templates and global search. Engage stakeholders early to define governance and ensure that data captured today will serve tomorrow’s AI use cases. Finally, explore how digital maturity can extend into new services or partnerships, turning internal capabilities into ecosystem value.
As the industry embarks on the next wave of AI-enabled discovery, those organizations with robust data foundations will lead. MacroGenics’ journey—from paper notebooks to a unified R&D platform, and onward—demonstrates how investing in data strategy not only accelerates internal development but also empowers broader collaboration through CDMO services. In an era when speed, agility, and predictive insights define competitive advantage, life science leaders must act now: strengthen data ecosystems, foster user-centric adoption, and chart a clear path towards AI integration. Only then can the full promise of AI in antibody therapeutics—and beyond—be realized.
